Synthetic oligonucleotides have recently been the object of many investigations aimed to develop sequence-selective compounds able to modulate, either positively or negatively, transcription of eukaryotic and viral genes. Alteration of transcription could be obtained by using synthetic oligonucleotides mimicking target sites of transcription factors (the transcription factor decoy -TFD-approach). This could lead to either inhibition or activation of gene expression, depending on the biological functions of the target transcription factors. Since several transcription factors are involved in tumor onset and progression, this issue is of great interest in order to design anti-tumor compounds. In addition to oligonucleotides, peptide nucleic acids (PNA) can be proposed for the modulation of gene expression. In this respect, double-stranded PNA-DNA chimeras have been shown to be capable to exhibit strong decoy activity. In the case of treatment of breast cancer cells, decoy oligonucleotides mimicking CRE binding sites, promoter region of estrogen receptor α gene, NF-kB binding sites have been used with promising results. Therefore, the transcription factor decoy approach could be object of further studies to develop protocols for the treatment of breast cancer. In the future, transcription factors regulating cell cycle, hormone-dependent differentiation, tumor invasion and metastasis are expected to be suitable targets for transcription factor decoy.
Introduction
Therapeutic approaches employing pharmacologically-mediated alteration of gene expression are expected to be in the near future of great interest for the treatment of many human pathologies, including neoplastic diseases (1-3). Among gene expression modifiers, several agents have been shown capable of specifically altering gene transcription, including DNA-binding drugs (4-15), triple-helix forming oligonucleotides (TFO) (16-21), decoy oligonucleotides (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . The target molecules of both DNA-binding drugs and TFO are the promoter sequences of the genes whose expression should be modulated (12-14, 16, 17) . Sequenceselective interactions of DNA-binding drugs and TFO with DNA leads to inhibition of the molecular interactions between regulatory transcription factors and target promoter sequences. For instance, we have reported that the G+C selective DNA-binding drugs mithramycin and chromomycin suppress molecular interactions between the transcription factor Sp1 and viral and eukaryotic promoters, possibly causing the alteration of expression of Sp1-regulated transcriptional units, including the oncogenes Ha-ras and c-myc (13, 39) . On the contrary, the target molecules of decoy oligonucleotides are transcription factors. Accordingly, the transcription factor decoy (TFD) approach is based on the competition for trans-acting factors between the endogenous ciselements present within the regulatory regions of the target gene and exogenously added decoy molecules (DNA-based drugs or analogues) mimicking the specific cis-elements (24, 29) . The objective of this molecular intervention is to cause an attenuation of the authentic interactions of trans-factors with their cis-elements, leading to a removal of the trans-factors from the endogenous cis-element inside the cell (32, 38) .
Alteration of Gene Expression by the TFD Approach: Activation of Silent Genes or Transcriptional Repression of Expressed Genes
The TFD approach is able to cause not only inhibition, but also activation of gene expression, depending on the biological role of the target transcription factor. Figure 1A shows that inhibition of gene expression could be obtained using decoy molecules inhibiting the molecular interactions between a transcription activator factor (TFa) and specific target promoter regions (28, 31, 33, 36) . Figure 1B shows that, conversely, activation of gene expression could be obtained using a decoy molecule interacting with a transcription repressor (TFr) (38) . Accordingly, if the objective of TFD is to block gene transcription (as in the case of oncogene expression), the decoy molecules should be targeted to activators of transcription; by contrast, if the objective of TFD treatment is the activation of silent or down-regulated genes (as for instance in the case of reactivation/modulation of tumor suppressor genes) the TFD molecules should be designed to target silencer factors.
Selection of the Target Transcription Factor(s) and Design of TFD Molecules
One of the most important parameters in developing a TFD approach suitable for antitumor treatment is represented by the identification of the target transcription factor(s). Transcription factors involved in neoplastic transformation and the relative consensus DNA sequences can be found within recently published compilations (40) (41) (42) (43) (44) (45) (46) . While TFD molecules could be easily designed to interact with all the transcription factors whose binding nucleic acid sequence is known, it should be carefully considered that regulation of gene expression in eukaryotes is a very complex phenomenon and that, in most cases, genes are regulated at the transcription level by cooperative effects of different transcription factors, whose activity is also influenced by chromatin status. In this case, it could be proposed the employment of short TFD molecules carrying binding sites for different transcription factors or PCR products mimicking large regulatory regions of the gene(s) to be pharmacologically controlled. Although double-stranded DNA oligomers are the most widely studied among efficient TFD molecules, several research groups employed large DNA molecules and/or structural modifications designed to enhance the stability and biological effects of these nucleic acids-based drugs. Recent studies have proposed the cross-linking between two DNA molecules to form a single-stranded molecule folded on itself, either via photocrosslinking (47) or by the introduction of a covalently linked, non nucleotide bridge (48). RNA decoys have been also described able to bind transcription factors via an aptameric interaction (49). In addition, circular decoys assuming a dumbbell configuration (50) or single-stranded decoys with a palindromic sequence that can fold on themselves (51) have been described. Decoy molecules were also produced by performing polymerasechain reaction (PCR) using primers amplifying regulatory regions of the target genes. This approach could be of great interest to modify gene expression following the identification of promoter regions playing positive or negative roles in regulation of transcription.
In Vitro Evaluation of the Decoy Activity of TFD Molecules
The in vitro evaluation of the biological activity of the designed decoy molecules is routinely assessed by molecular technologies, such as gel retardation (13), competitive DNase I footprinting (52), in vitro transcription (39). In addition to these analytical techniques, the recently described biospecific interaction analysis (BIA) employing surface plasmon resonance (SPR) and biosensor technology could be very informative (53-57). SPR-based BIA allows the monitoring of molecular reactions in real-time (53), including transcription factors-DNA interactions (52, (56) (57) (58) (59) (60) . In a typical experimental set-up employing either flowbased and cuvette-based biosensors, incident light is reflected from the internal face of a prism in which the external face has been coated with a thin metal film. At a critical angle, the intensity of the reflected light is lost to the creation of a resonant oscillation in the electrons at the surface of the metal film (54). Since the critical angle is dependent on the refractive index of the material present on the metal surface, this real-time method has been used to measure molecular interactions between a ligand immobilized at the sensor surface and suitably added analytes (56-60).
SPR-based BIA offers many advantages with respect to most of the other available methodologies to study biomolecular interactions between DNA and transcription factors (56-58), including the fact that no labeling is required, the amount of both ligand and analyte needed to obtain informative results is low (less than 0.5 µg of DNA and 1 µg of protein are necessary to generate suitable surfaces) and the assay is rapid, usually requiring 20-25 minutes for ligand immobilization and 4-5 minutes for a complete characterization of ligandanalyte interactions (it should be noted that the binding is a real-time interaction analysis, leading to informative results at the same time the binding occurs). In addition, most commercially available biosensors are fully automated instruments, a large variety of activated sensor chips are commercially available allowing the immobilization of either proteins or target DNA, the sensor chip could be re-used many times, leading to low running costs, with the only limitation of verifying the stability of the immobilized ligand (56, 57). Figure 2 shows the use of SPR-based BIA to study the interactions between an injected transcription factor and a target double-stranded DNA immobilized on the sensor chip (Figure 2A and 2B ). In addition, Figure 2C shows the expected sensorgrams when the transcription factor is either injected in the absence (solid line) or in the presence (dotted line) of a decoy biomolecule. In this case binding to the target DNA is significantly lower, in relation to the activity of the decoy molecule employed.
TFD in Pharmacotherapy: Applications to Breast Cancer
The State-of-the-Art Although few papers have reported the application of the TFD strategy on breast cancer cells, the published studies here reported encourage the research in this field.
One example of application of TFD to breast cancer cells is represented by CRE-decoy oligonucleotides. CRE has been described as the consensus sequence for the cis-element that directs cAMP-induced gene transcription. Several CRE transcription factors have been implicated in the regulation of many cellular processes, including cell growth and dif- gives evidence for the binding of the transcription factor to the target DNA. No decrease of RU was obtained after injection of binding buffer to preformed complexes (segment c), demonstrating stability of the TF/DNA complex. The sensor chip is regenerated after injection of 50 mM NaOH (segment d). Panel C shows the sensorgram expected following injection of the transcription factor (solid line) or the transcription factor pre-incubated with decoy molecules (dotted line) (modified from refs. 52, 56 and 57). Segment b: injection of TF or TF/decoy complexes; segment c: injection of binding buffer. ferentiation (61). Recent data by demonstrated that a CRE-decoy oligonucleotide produces growth inihibition in breast cancer cells but not in normal cells. Cyclin D1 is one of the genes targeted by CRE decoy since the antitumor effects detected after CRE decoy treatment were found to be correlated with the inhibition of cyclin D1 expression and cyclin D1/Cdk4/pRB signaling (63). E. Southwestern blot of protein extracts. Cell extracts from MDA-MB-231 and MCF7 cells were separated by electrophoresis on polyacrylamide gel, transferred to nitrocellulose and renatured. To detect the proteins that bind to the DNA-102, the nitrocellulose sheet was incubated with 5' 32 P-end labeled specific DNA-102 probe. After washing, the membrane was exposed to X-ray film. A second example of the decoy approach is that finalized to modify the effects of steroid hormones, in particular estrogen and progesteron. These molecules play very important roles in induction and growth of breast cancer (64). Several experimental evidences demonstrated indeed that alterations in both estrogen signaling and progesteron signaling occur during breast tumorigenesis and breast cancer progression (65). This is demonstrated by alteration of estrogen (ER) and progesteron (PR) receptor isoforms expression, affecting, directly or indirectly, the activity of ER signal transduction pathways during tumorigenesis and progression of breast cancer (66, 67). A commonly emerging theme is the marked alteration of estrogen action occurring during these processes.
Treatment of Breast Cancer with Transcription Factor Decoys 407

Piva and Gambari
Our research group, in the attempt to identify specific molecular TFD targets for the treatment of breast cancer cells, developed a decoy strategy against a regulatory region of the P3 distal promoter (renamed promoter C according to the recent suggested nomenclature) (68) of the ERα gene (see Figure 3A ). By treating breast cancer cells with a specific decoy molecule mimicking a sequence of P3 upstream ERα promoter (named DNA-102, -3258/-3157) we obtained not only an increase of ERα RNA in MCF7 ERα positive cells, but also a reactivation of ERα gene transcription in MDA-MB-231 (ERα negative breast cancer cells) ( Figure 3B ) (69, 70) . In addition, the analysed cells exhibit a decrease in cell growth after decoy treatment (70). Immunocytochemical and Western blot analysis revealed that this decoy treatment was able to induce a reactivation of ERα expression also at protein level (representative results are shown in Figure 3 , C and D). In addition, we demonstrated by Southwestern analysis that a nuclear factor of 110 kD in size, able to bind an oligomeric sequence inside DNA-102, was present only in the ERα negative cells analyzed ( Figure 3E ). This DNA-protein interaction was also demonstrated by in vitro footprinting analysis ( Figure 3F ). Our experiments suggest that a putative regulatory factor with negative regulatory properties was among the factors trapped by DNA-102 decoy molecule in the transfection experiments. To our knowledge, this is the first demonstration that a decoy with a specific DNA sequence of ERα upstream region exerts a direct positive effect on ERα gene expression.
The target transcription factor(s) of the third example of TFD approaches relevant to breast cancer treatment belongs to the NF-kB superfamily (71, 72). The RelA subunit of NF-kB transcription factor (but not the NFKB1 subunit) causes pronounced inhibition of tumor cell growth in vitro and in vivo.
Both the subunits of NF-kB can form homo-or heterodimers with other members of the Rel oncogene family (71-73). In an effort to decipher the role of homo-vs heterodimeric NF-kB in regulating tumor cell growth, Sharma et al. have used a decoy approach to trap these complexes in vivo (73). Using double-stranded phosphorothioate ODNs as direct in vivo competitor for homo-vs heterodimeric NF-kB, they demon-strated that decoy molecules specific to RelA inhibit growth of breast tumor cells in vitro. Such transcription factor decoys can be a non-antisense tool to alter breast cancer cell growth.
Future Perspectives
Transcription factors or co-regulators of transcription factors that bind specific regulatory regions of genes involved in growth control, maintenance of differentiated epithelial functions and invasiveness may play a critical role in breast tumorigenesis. They represent potential targets for the design of TFD molecules for control of breast tumor growth to be assayed with appropriate cell systems. At this purpose, the identification of specific gene targets associated with the breast cancer phenotype, and the accurate analysis of the regulatory regions inside their promoter(s) are critical to obtain useful information for the development and application of TFD intervention. Therefore, disruption of specific signaling pathways or reduction in the expression of the proteins, that are below summarized, would be of interest to revert breast cancer phenotype.
Cell Cycle
With the recent explosion of knowledge in the field of cell cycle, several genes that partecipate to its regulation have been identified and characterized. Multiple components of the so-called cell cycle machinery, such as cyclins, Cdks, CDKIs, Rbs, E2Fs are involved in the cell cycle phases transition (74). E2F-1 is the better characterized member of this gene family; several lines of evidence indicate that it is involved in tumor development and that its overexpression can drive quiescent cells or induce G1 arrested cells into S phase (75, 76). Alterations of the cyclin/Cdk/Rb pathway have been frequently observed in breast carcinomas (77). In particular, overexpression of cyclin D1 and cyclin E, low levels or absence of Rb, p16 and p27 have been observed (78). A gradual increase of E2F-1 expression from normal to outright malignancy was found (76) suggesting that overexpression of E2F-1 may be involved in the development of breast invasive ductal carcinomas. E2F-1 exhibit advantages over other biomarkers, such as Mib-1 antigen, because it is a well-known cell cycle regulating protein. The Mib-1, Ki-67, is a very popular marker of cell proliferation, but its role in cell cycle is unknown (76). Therefore, E2F-1 (a transcription factor with a well described molecular role) may be considered not only a promising candidate to become a new prognostic/predictive marker of breast cancer, but also a molecular target for the development of specific nucleic acid based drugs as novel anti-cancer therapeutics.
The Bone Morphogenetic Proteins (BMPs) belong to a large family of growth factors, including activins and TGF-β (79). The role of the BMPs in the control of breast cancer cell pro-liferation is described, and recent observations shows that BMPs can inhibit in vitro breast cancer cell proliferation (80, 81) . The identification of the factors controlling BMP production and action in breast cancer cells will be of great interest. It was demonstrated that BMP-2 induces p21 promoter activity by BMP receptors initiating BMP signal transduction by phosphorylating and activating Smad1. Smad1 would then cooperate with other transcription factors to activate the transcription of the p21 promoter. High levels of the p21 protein would then bind and inhibit the cyclin E-cdk2 complex, arresting breast cancer cells in G1 phase of the cell cycle.
Hormone Dependent Differentiation
Years of investigations have indicated that not only growth factors-, integrin-and steroid hormone-signaling pathways play an important role in maintaining the structure and function of the mammary gland, but also an increasing number of coactivators/cointegrators or corepressors proteins that, in particular, enhance or inhibit transactivation of one or more nuclear receptors (NRs). The NRs are transcription factors including the steroid/thyroid hormone, retinoid and vitamin D receptors and a growing number of orphan receptors for which endogenous ligands have not been identified. Experimental approaches aimed at determining a good target for an effective and specific decoy strategy could be also addressed to study several classes of proteins interacting with these NRs and able to enhance or inhibit their activity (66, 82). These interacting proteins include SRC (p160 steroid receptor coactivators) (83), p300/CBP and p300/CBP-associated factor (PCAF) (84), which enhance transcriptional activation of NRs, also exibiting histone acetyltransferase activity that facilitate access of transcription factor complexes to NR-responsive elements. Other interacting proteins have been characterized, including TRIP/SUG1 (a component of the PA700 proteasome complex) (85), hBrm and BRG1 (ATP-dependent chromatin-remodeling factors) (86), SNURF (a RING finger protein) (87), E6-AP (an E3 ubiquitin protein ligase) (88), HMG-1/2 (chromatin high mobility group proteins) (89), Zac1 (a zinc finger transcription factor) (90), p68 (an RNA helicase) (91), CARM1 (an arginine methyltransferase) (92), TIF1 (a protein kinase) (93), caveolins (proteins interacting with signaling molecules) (94) and SRA (a steroid receptor RNA activator) (95). Members of a complex group of related proteins that include vitamin D receptor-interacting proteins (DRIP), cofactors required for Sp1 (CRSP), activated recruited cofactors, and thyroid hormone-associated proteins (TRAP) (96) are also able to coactivate ER and other NRs. These last proteins do not exhibit histone acetyltransferase activity, and a recent study using a chromatin immunoprecipitation assay showed that both SRC-3 and DRIP205 are recruited to the estrogen-responsive region of the cathepsin D gene promoter after treatment of MCF-7 cells with 17-β-estradiol (97). The ligand-and gene-specific recruitment of these factors is very complex, and their expression is certainly regulated in a specific cellular enviroment way. They represent potential pathway of protein-protein and DNA-protein interactions of relevance in breast cancer onset and progression.
Tumor Invasion and Metastasis
Constitutive activation of NF-kB has been shown to be involved in the progression of breast cancer cells to a highly invasive phenotype (73, 98) . The expression of proteolytic enzymes such as metalloproteinases and urokinase-type plasminogen activator (uPA), that are involved in degradation of tissue barriers and cell migration, is induced by . A direct link between activation of NF-kB and phosphatidylinositol (PI) 3-kinase, (constitutively active in highly invasive breast cancer cells) has recently been demonstrated (73). The inhibition of PI 3-kinase reduced the activation of NF-kB and PI 3-kinase and NF-kB inhibition repressed the migration of breast cancer cells (73).
Another interesting factor to be investigated is the trefoil fac- tor (TFF) 1. TFF1 acts as motogen for breast tumor cells, promoting their dissemination and facilitating invasion of surrounding tissue (100). It is possible that beneficial effects of anti-estrogen therapy may be due in part to a reduction in the expression of TFF1, but inhibition of tumor cell dissemination is expected to be also obtained with specific decoy against regulatory region of the TFF1 gene promoter.
Several research groups (101, 102) have reported that the deregulated expression of Id-1 is one of the major causes for the development of a metastatic phenotype in breast cancer cells. Id-1 protein is defined as "Inhibitor of differentiation" or "Inhibitor of DNA binding". It belongs to a family of HLH (Helix-Loop-Helix) proteins that bind to and inhibit the activity of basic helix-loop-helix (bHLH) transcription factors. These bHLH are able to activate the transcription of genes involved in cell differentiation, but when ectopic expression of Id proteins is developed, an inhibition of differentiation of a wide variety of cell types was detected. Based on experimental evidences, a mechanism for differential regulation of Id-1 promoter in aggressive and nonaggressive breast cancer cells was observed.
WT1, originally identified as a tumor suppressor gene responsible for Wilms' tumor, is a zinc finger protein acting as a transcription factor for many genes regulating renal cell differentiation and growth, and its tumor-suppressive function has been proposed to be due to transcriptional repression of growth factors, including IGF-II, IGF-I receptor, platelet-derived growth factor-A, transforming growth factor-β, c-myc, and bcl-2 (103). Recently, Loeb et al. (104) have demonstrated that WT1 protein is expressed in nearly 90% of breast cancers but not in most normal breast tissues. These results suggest that WT1 plays a certain role in the pathogenesis of breast cancer as an oncogene but not a tumor suppressor gene in analogy to leukemia (105). Silberstein et al. (106) studied the WT1 expression by immunohistochemistry and demonstrated an association of WT1 protein expression with a biologically aggressive phenotype of breast cancer such as ER negativity. Xie et al. (107, 108) have demonstrated that prominent expression of the genes coding for CTGF (connective tissue growth factor), WISP-1 (Wnt-induced secreted protein) and CYR61 (cysteine-rich 61) is associated with an advanced stage of breast cancer at diagnosis. In particular, several studies have suggested that CYR61 may be involved in estrogen-mediated tumor development (109, 110) . These proteins, belonging to CCN family, are involved in stimulation of cell proliferation, migration, adhesion, and extracellular matrix formation. They also regulate more complex biological processes, such as angiogenesis and tumorigenesis (111). The understanding of the aberrant signaling pathways activated by high levels of expression of these CCN proteins may offer useful therapeutic targets (111).
Another important aspect in the management of breast cancer patient is the metastatic bone diseases. It has been recognized that breast cancers have the ability to invade and grow as metastases in bone (112, 113) . Accumulating evidences indicate that the osteoclast differentiation factor (ODF), a member of tumor necrosis factor (TNF) family also known as TRANCE (TNF-related activation-induced cytokine) or receptor activator of NF-kB ligand (RANKL), is the final extracellular mediator that, acting on osteoclast precursors, induces the differentiation into mature osteoclasts (114) with suppression of osteoprotegerin osteoclastogenesis inhibitory factor (115). This mechanism may be an important target for therapeutic approches aimed to control and prevent bone metastasis.
It is important to underline that recently developed technologies, such as DNA microarrays and SAGE (serial analysis of gene expression) have made it possible to obtain comprehensive gene expression profiles of breast carcinomas of all stages. The application of these genomic approaches in combination with the complete sequence of the human genome and extensive molecular epidemiological studies is likely to further our understanding of the molecular basis of mammary tumorigenesis and will identify targets for risk prediction, cancer prevention and treatment.
TFD Approach and Gene Therapy: Advantages and Drawbacks
A major advantage of the decoy pharmacotherapy is related to the fact that the reachment of a phenotypic objective could need the modulation of different genes in a coordinated fashion. In fact, several experimental and computational reports show that multiple coordinated genes could be under the control of a same, or a limited numbers of TF (43) (44) (45) 96) . On the other hand, the possible multiplicity of transcription factors regulating the expression of a given target gene and the multiplicity of target unrelated genes, that are under control of a single transcription factor, represent important limitations to the TFD strategy. Specificity becomes an even greater challenge when target gene expression is to be inhibited only in a single organ or tissue type, since systemic delivery of the DNA (the most used TFD molecule) is likely to lead to widespread uptake and potential nonspecific side effects (32, 51).
In addition, as with other ODN strategies, the successful use of TFD treatment will almost always depend on an efficient delivery of the synthetic DNA to target cells.
Although one recent report describes a mechanism by which decoy binding in the cytoplasm prevents nuclear translocation of NF-kB (23), for most applications, decoy ODNs are thought to require nuclear localization if they are to prevent the transactivation of their target genes. Unfortunately, the endocytotic pathways translocate most of the ODN into lysosomal compartments, where they are efficiently degraded.
In agreement with these considerations, the search for decoy biomolecules exhibiting on one hand efficient decoy activity, on the other hand resistance in serum and cellular extracts appears to be one of the major issue in pharmacological research in this field.
Novel TFD Molecules Based on Peptide Nucleic Acids (PNAs)
Peptide nucleic acids (PNAs) are recently described DNA mimics in which the sugar-phosphate backbone is replaced by N-(2-aminoethyl)glycine units (116, 117) . These molecules efficiently hybridize with complementary DNA, forming Watson-Crick double helices (116). The interest of PNAs and PNA-based analogues for gene therapy are related to the fact that they are resistant to DNases and proteinases; accordingly, they have been proposed in antisense and antigéne therapy in a great number of studies (118-130).
While the possible use of PNAs for targeting mRNA molecules and genomic sequences is well documented (124-130), few reports are available on the possible use of PNA-based double stranded molecules to target transcription factors (52, 130) . This is due to the fact that double-stranded PNA/PNA and PNA/DNA hybrids exhibit structural features significantly different from those of DNA/DNA hybrids (124). This feature affects direct binding of transcription factors to target PNA-based molecules, as well as stability of the generated complexes (52, 131) . With respect to the TFD approach, promising results have on the contrary obtained using doublestranded PNA-DNA chimeras (132). PNA-DNA chimeras are DNA molecules composed of a part of PNA and a part of DNA ( Figure 4A) . We have designed and tested PNA-DNA-PNA chimeras mimicking NF-kB binding sites (133, 134) . In these studies, PNA-DNA-DNA (PDP) chimeras carrying the NF-kB binding sites were analysed by circular dichroism and gel shift assay; the results obtained give clear evidence for an efficient decoy activity by these molecules. Interestingly, PNA-DNA chimeras are expected to be (i) more resistant than DNA/DNA hybrids to nucleases, (ii) suitable for delivery with cationic liposomes and (iii) more soluble than PNAs (130, 133). The results obtained are the first observation that PNA-based molecules could be proposed for TFD pharmacotherapy. Figure 4B shows a representative example of the data obtained, indicating that PDP/PDP and DNA/PDP molecules (but not DNA/PNA and PNA/PNA hybrids) are able to inhibit the molecular interactions between p52 NF-kB transcription factor and the target 32 P-labeled NF-kB synthetic oligonucleotide (133, 134) .
With respect to the expected advantages of using TFD molecules based on PNA-DNA chimeras, we like to mention that the relative length of PNA and DNA stretches could affect the affinity of the target transcription factor to the TFD biomolecule; therefore, these reagents appear to be flexible in their biological applications. In addition, short peptides recognized by cellular receptors expressed by target cells could be linked to the PNA stretch at the end of the TFD molecule, thereby facilitating delivery (130).
Conclusions
Synthetic oligonucleotides have recently been the object of many investigations aimed to develop sequence-selective compounds able to modulate, either positively or negatively, transcription of eukaryotic and viral genes . This issue is of great interest in order to design anti-tumor compounds and anti-viral agents, as well as compounds able to induce cellular differentiation. Alteration of transcription could be obtained by using synthetic oligonucleotides mimicking target sites of transcription factors (the decoy approach) (23-38). This could lead to either inhibition or activation of gene expression, depending on the biological functions of the targeted transcription factors (see Figures 1 and 3 ).
Furthermore, peptide nucleic acids (PNA) can be proposed for the modulation of gene expression. In this respect, doublestranded PNA-DNA chimeras (133, 134) have been shown to be capable to exhibit strong decoy activity (see Figure 4 ).
In the case of treatment of breast cancer cells decoy oligonucleotides mimicking CRE binding sites (61-63), estrogen receptor promoter region (Figure 3 and refs. 68-70), NF-kB binding sites (71-73) have been used with promising results. Therefore, TFD could be object of further studies to develop protocols for the treatment of breast cancer.
In the future, transcription factors regulating cell cycle, hormone-dependent differentiation, tumor invasion and metastasis are expected to be suitable targets for TFD treatment of breast cancer cells. 
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